Cart
sales@molnova.com
Cyclo(-RGDfK) TFA
CAS No. 500577-51-5
Cyclo(-RGDfK) TFA( —— )
Catalog No. M22892 CAS No. 500577-51-5
Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 164 | In Stock |
|
| 5MG | 96 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 384 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCyclo(-RGDfK) TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionCyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
-
DescriptionCyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorαVβ3 integrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number500577-51-5
-
Formula Weight717.69
-
Molecular FormulaC29H42F3N9O9
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (139.34 mM; Need ultrasonic); H2O:33.33 mg/mL (46.44 mM; Need ultrasonic)
-
SMILESC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O.C(=O)(C(F)(F)F)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
molnova catalog
related products
-
RBC8
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
-
α2β1 integrin-IN-15
α2β1 integrin-IN-15 highly potent, selective, allosteric small-molecule inhibitor of integrin α2β1 with IC50 of 12 nM.
-
Roxifiban acetate
Roxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
